BRAF and metastatic melanoma: Approximately 4% of all patients diagnosed with the disease each year suffer from stage 4 metastatic melanoma (2), The averaged 3-year overall survival (OS) rates were 41.3% for BRAF plus MEK inhibitor, 49.9% for PD-1 inhibition, and 58.4% for CTLA-4 plus PD-1 inhibition, in first-line therapy (3), a highly concerning statistic.